Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial-Reference-Cited by-同舟云学术

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Published:2017-06 Issue:6 Volume:18 Page:743-754
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Krop Ian E,Kim Sung-Bae,Martin Antonio Gonzalez,LoRusso Patricia M,Ferrero Jean-Marc,Badovinac-Crnjevic Tanja,Hoersch Silke,Smitt Melanie,Wildiers Hans

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate;Lewis Phillips;Cancer Res,2008

2. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

3. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial;Diéras;Lancet Oncol,2017

4. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial;Krop;Lancet Oncol,2014

5. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

Cited by 404 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation;npj Precision Oncology;2024-09-09

2. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China;Cancer;2024-08-02

3. Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis;Discover Oncology;2024-08-02

4. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

5. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28